Smart Drugs for Smarter Stem Cells: Making SENSe (Sphingolipid-Enhanced Neural Stem Cells) of Ceramide

Erhard Bieberich

Program in Developmental Neurobiology, Institute of Molecular Medicine and Genetics, School of Medicine, Medical College of Georgia, Augusta, Ga., USA

Introduction and Overview

Ceramide is a membrane-resident sphingolipid and metabolic precursor for sphingosine, sphingosine-1-phosphate (S1P), ceramide-1-phosphate, sphingomyelin, and glycosphingolipids (fig. 1a, b). In addition to being important in stabilizing cellular membranes, sphingolipids have emerged as second-messenger lipids in cell signaling pathways that regulate apoptosis, cell polarity, and differentiation. The ability of sphingolipids to form lipid microdomains or rafts determines their unique role as interface between extracellular growth factors or cytokines, and intracellular cell signaling pathways. Of particular significance is the enzymatic conversion of sphingomyelin to ceramide in the cell membrane, which is triggered by pro-apoptotic cytokines (fig. 1a). Our group has, for the first time, introduced the hypothesis that ceramide microdomains organize SphingoLipid-Induced Protein Scaffolds (SLIPS) on the inside of the cell [1]. We have provided evidence that SLIPS are initiated by the direct association of ceramide with atypical PKCζ/λ (aPKC), a protein kinase C isoform essential for cell adhesion, polarity, apoptosis, and inflammation [2, 3]. We hypothesize that the outcome of this association depends on the specific composition of proteins that participate in ceramide-induced...
SLIPS. For example, if cells express high levels of prostate apoptosis response 4 (PAR-4), an inhibitor protein of aPKC, ceramide will induce binding of PAR-4 to aPKC. PAR-4-mediated inhibition of aPKC will then result in apoptosis [2, 4–6]. If cells express low levels of PAR-4, ceramide will promote association of the small GTPase Cdc42 with aPKC and sustain cell polarity [3].

We have proposed to utilize these ceramide-induced protein interactions for the controlled differentiation of embryonic stem (ES) cells [1]. Instead of using water-insoluble ceramide, we have synthesized a novel ceramide analog, N-oleoyl serinol (S18), that is water-soluble, enriches in cellular membranes, and binds to aPKC [7, 8]. Our group has shown for the first time that S18 can be used to eliminate residual pluripotent cells from an ES cell-derived neural progenitor or precursor cell (NPC) graft [5]. If contaminated with pluripotent cells teratomas (stem cell tumors) will form after transplantation of NPCs into mouse brain. We have used S18-induced apoptosis of these cells to prevent teratoma formation, an important step toward safer stem cell therapy [5, 9].

In new studies, however, we found that a small portion (<5%) of useful NPCs express PAR-4. These cells, termed NPC2 cells, are lost after incubation with S18. NPC2 cells express the receptor SIP1 that induces anti-apoptotic cell signaling pathways when activated by binding to SIP [10–14]. Our results suggest that activation of SIP1 by incubation with SIP protects NPC2 cells from S18-induced apoptosis and promotes oligodendroglial differentiation. Accordingly, a combination of S18 and SIP (or the SIP pro-drug analog FTY720) eliminates tumor-forming stem cells and the same time triggers differentiation of NPCs. The present review will discuss the significance of sphingolipids for stem cell differentiation and show recent results from our laboratory on the use of sphingolipids for the design of novel stem cell therapies.

Sphingolipids: An Enigmatic Species of Cell Signaling Lipids

The term sphingolipids dates back to 1884 when the German pathologist and ‘father of neurochemistry’ Johann Ludwig Wilhelm Thudichum (1829–1901) first described a class of new lipids derived from the base sphingosine (fig. 1a) [1]. He coined the term ‘sphingolipids’ (from Greek ‘sphingos’, genitive of Sphinx), suggesting they were as mysterious as the Sphinx herself. To date, more than one hundred different sphingolipids are known. They are essential components of cellular membranes and have been implicated in a variety of biological functions (fig. 1b). Among these, their roles as pro- or anti-apoptotic and pro- or anti-proliferative signaling lipids are the most important. To establish a profile of these functions for individual sphingolipids is difficult because of their rapid metabolic interconversion (fig. 1b).

A major drawback in understanding the function of sphingolipids is that it is mostly not known with which proteins they interact. Binding partners and even specific binding domains have been identified for many other signaling lipids. For example, diacylglycerol, an important pro-proliferative lipid, interacts with the C1 domain of classical protein kinase C (PKCα) and protein kinase D (PKD) [15–19]. Phosphoinositols, another class of signaling lipids, bind to the pleckstrin homology (PH) domain [19, 20]. Once a protein domain of this type has been identified it can be predicted from the amino acid sequence that the protein will bind to the cognate lipid. For sphingolipids, binding partners have only been specified for ceramide [2, 8, 21–30], ceramide-1-phosphate [31–33], S1P [34–37], and some gangliosides (e.g. GM1). In most cases, it is still not clear which conserved protein domain will interact with a particular sphingolipid.

The ‘classical’ interaction partners of ceramide are ceramide-activated protein phosphatase(s) [22, 23, 38] and kinase(s) [8, 24, 25, 27, 28, 30, 39–43]. Recent studies have shown that ceramide activation of protein phosphatase 1 (PP1) alters splicing of B-cell lymphoma X (bcl-x) and caspase 9 from anti- to pro-apoptotic proteins [44]. Ceramide-activated protein phosphatase 2A (PP2A) is involved in de-phosphorylation of a variety of key factors in cell signaling pathways regulating proliferation, apoptosis, and differentiation [22, 38, 45].

Within the group of protein kinases, kinase suppressor of Ras (KSR) [46, 47], PKCδ [42, 43], and aPKC [2, 3, 8, 24–28, 45] have been found to be activated by ceramide. In the last 10 years, activation of aPKC by ceramide was independently confirmed by several groups [2, 8, 24–28]. A relative of the C1 domain, the C1B domain was identified in the amino acid sequence of PKCδ and aPKC. Because of its structural similarity to diacylglycerol, ceramide has been suggested to bind to this domain [15, 40–42]. It was not until recently, however, that evidence for direct binding of aPKC to ceramide was found [2, 8, 24, 26, 27]. Our own studies have focused on aPKC based on its affinity to ceramide and novel ceramide analogs [2, 8]. Ceramide and most likely many ceramide analogs form organized lipid microdomains or rafts in the cell membrane [26, 48–54]. These rafts may allow for repeated and multiple binding (avidity) of ceramide-associated proteins, thereby enhanc-
ing the formation of protein complexes with cell signaling functions. Therefore, it is tempting to speculate that ceramide-induced rafts and associated protein complexes form an initial platform for growth factor or cytokine-dependent cell signaling pathways.

**Lipid Rafts and SLIPS: A Platform for Cell Signaling Pathways**

Three major cell signaling pathways are regulated by cytokines and growth factors that activate sphingomyelinases, a group of acidic or neutral pH-dependent enzymes that elevate the ceramide concentration in the cell membrane by catalyzing the hydrolysis of sphingomyelin (fig. 1a). Two of these cell signaling pathways, CD95/FasL and TNFα, are known to induce apoptosis in a variety of cell types by the activation of acid sphingomyelinase (ASMase). In contrast to the cytokine-activated receptors, the p75NTR cell signaling pathway is not a priori pro-apoptotic. The neurotrophin receptor p75NTR is expressed by many neural cell types and induces axonal outgrowth in the peripheral nervous system when stimulated with nerve growth factor (NGF) [63–67]. However, evidence has amounted that p75NTR-induced apoptosis is a major factor in neurodegenerative diseases such as Alzheimer’s disease [68–76]. This apparently paradoxical, dual function of p75NTR, pro-apoptotic or pro-outgrowth, has been explained by a model suggesting that the effect of p75NTR activation depends on heterodimerization with other neurotrophin receptors [77–87]. If p75NTR forms heterodimers with tropomyosin-related kinase A (trkA), a tyrosine kinase receptor, activation of the chimeric receptor induces axonal outgrowth. However, if p75NTR forms homodimers binding of NGF to p75NTR activates neutral sphingomyelinase (NSMase), which then generates ceramide and may induce apoptosis.

For a long time, ceramide was stigmatized as being an exclusive inducer of apoptosis. This bias resulted mainly from experiments that used a short chain analog of ceramide, N-acetyl sphingosine (C2 ceramide) to test the induction of apoptosis by ceramide. C2 ceramide is ideally suited as medium supplement because its water solubility is severalfold higher than that of physiological ceramide species (e.g. N-palmitoyl sphingosine or C16 ceramide). However, recent advances in administering ceramide with long fatty acid chains and the development of novel ceramide analogs has clearly shown that ceramide has additional, non-apoptotic functions [2, 3, 7, 8, 88–92]. In particular, our group has demonstrated that the pro- or non-apoptotic function of ceramide depends on effectors that modulate the activation of ceramide-associated proteins [2–5].

Ceramide has been shown to form microdomains or rafts within cellular or synthetic membranes [26, 41, 48, 51, 54, 56, 93]. Lipid rafts are originally characterized by being insoluble in detergent. Using this unique feature to isolate rafts many membrane-resident proteins have been characterized as being raft or non-raft proteins. Unfortunately, it has turned out to be difficult to directly visualize these rafts, which is important to show their biological significance. One of the main reasons for this shortcoming was the unavailability of antibodies against membrane lipids. With respect to ceramide, this has been tremendously improved within the last couple of years [94, 95]. For example, our group has developed a novel antibody against ceramide that was used to determine the polarized distribution of ceramide in membrane protrusions of neural cells and apical cell membranes of primitive ectoderm cells [3, 95].

How would the polarized distribution of ceramide in lipid rafts support its function as second messenger lipid for cell signaling pathways? We have to keep in mind that ceramide is mainly distributed to three compartments of the cell. De novo biosynthesis of ceramide from serine and palmitoyl-CoA takes place in the endoplasmic reticulum (ER) [96–99]. The hydrophobic alkyl chain of sphingosine and the fatty acid residue are buried within the membrane, while the polar head group of the sphingosine (serine) portion faces the cytosol. From the ER, ceramide is transported to the Golgi via ceramide transport protein (CERT) [97, 100]. In the Golgi, ceramide is derivatized by attaching phosphorylcholine or glycosyl groups, which generates sphingomyelin or glycosphingolipids, respectively. At this point, the polar head group has flipped from...
the cytosolic to the luminal part of the Golgi. Sphingomyelin and glycosphingolipids are transported to the cell membrane, the polar head group facing the outside of the cell. It becomes clear that any association of ceramide with cytosolic proteins will first require flipping the polar head group back to the inside of the cell.

It should be noted that other compartments, in particular mitochondria, the nucleus, and lysosomes contain ceramide pools as well. Ceramide has been suggested to open a mitochondrial transition pore, which releases pro-apoptotic proteins such as cytochrome c and apoptosis-inducing factor (AIF) [101, 102]. In the nucleus, ceramide could affect the alternative splicing of RNA encoding pro or anti-apoptotic proteins, or cause an imbalance of calcium levels [103, 104]. The lysosomes are known to generate ceramide via activation of lysosomal ASMase, an enzyme affected in Niemann-Pick disease [105]. Our laboratory has shown that elevation of ceramide in mitochondrial-associated membranes (MAM) of the ER induces a pro-apoptotic aPKC/PAR-4 complex that prevents activation of NF-κB [2]. However, we have also found that the non-apoptotic functions of ceramide are intimately linked to ceramide localized at the cell membrane.

Figure 2a depicts our working model that shows how the localized and receptor-mediated activation of SMases generates a ceramide raft. It should be noted that ASMase is localized at the outer leaflet, while NSMase is at the inner leaflet of the cell membrane [56, 58, 106]. Accordingly, activation of ASMase generates ceramide first at the outer leaflet, which is followed by flipping of the polar ceramide head group to the inner leaflet of the membrane. In contrast to ASMase, receptor-activated generation of ceramide by NSMase will first require flipping of the polar SM head group to the inner leaflet. Once ceramide is enriched at the inner leaflet, ceramide-binding proteins such as aPKC will initiate a SLIPS, a protein complex proposed by our group for the first time [1]. A SLIPS will promote microtubule formation and as a result, protrusion of the membrane. Depending on the effect of the receptor on SMases (activating or inhibiting), binding of a growth factor or cytokine may enlarge ceramide or SM microdomains, respectively. Intriguingly, studies with synthetic model membranes have shown that ceramide and SM form microdomains that are segregated from each other [50, 51, 58, 93]. Hence, receptor activation will polarize the distribution of these two sphingolipids when the ceramide microdomain expands. We should keep in mind that release of ceramide by SMases is an enzymatic process: receptor activation by binding of just one growth factor or cytokine molecule may generate many more ceramide molecules that organize themselves in microdomains or rafts.

Is there experimental evidence for our model? It has been shown that ceramide can rapidly flip from the outside to the inside of the cell membrane [107]. Flipping of SM has been suggested to go in hand with externalization of phosphatidylserine and may involve a phospholipid binding protein termed ‘scramblase’ or ‘flippase’ [108–111]. Hence, accumulation of ceramide or SM in rafts at the outer membrane leaflet will quickly generate an equivalent microdomain facing the cytosol. There is no direct evidence for this ‘inner leaflet’ microdomain coming from a recent study showing that the isolated ceramide raft fraction contains aPKC, clearly a ceramide-associated, cytotoxic protein [26]. There is also evidence that ‘ phosphatase and tensin homolog deleted on chromosome ten’ (PTEN), another cytosolic protein, is associated with ceramide rafts [112]. This, however, may not involve direct binding of PTEN to ceramide but association with a protein complex organized at the ceramide raft. Better evidence would be provided if we could directly visualize the association of a cytosolic protein with the ceramide raft.

We have used immunocytochemistry for sphingomyelin and ceramide to determine the distribution of these two sphingolipids in the cell membrane of NPCs (fig. 2b). Although sphingomyelin and ceramide domains are in close vicinity to each other, they show only little overlap in their membrane distribution [unpubl. results]. This result is consistent with our model in that ceramide, once generated from sphingomyelin, organizes itself in separate lipid domains. Notably, ceramide is mainly distributed to a perinuclear compartment and the tip of membrane protrusions. These protrusions may represent ‘sphingopodia’, a term we have introduced when we noticed the polarized distribution of ceramide in microspikes, filipodia and lamellipodia [95]. In previous studies, we have used fluorescence resonance energy transfer (FRET) to confirm the direct association of ceramide with aPKC in the ceramide-rich perinuclear compartment [2]. FRET is a technique that utilizes the direct, radiation-free energy transfer from one fluorophore to another one when they are close together (<10 nm). Figure 2c shows initial studies obtaining a Cy3-to-Cy5 FRET signal from α-tubulin (bound to Cy3-conjugated antibody) to ceramide (bound to Cy5-conjugated antibody) in membrane protrusions of NPCs. In summary, our studies support the model shown in figure 2a in that one of the non-apoptotic functions of ceramide may be the regulation of cell polarity and assembly of microtubules.
Fig. 2. From rafts to SLIPS. a Model for the formation of ceramide rafts by cytokine or growth factor-activated acid or neutral sphingomyelinase (A or NSMase). A ceramide-associated protein complex (sphingolipid-induced protein scaffold or SLIPS) is formed at the inner leaflet of the cell membrane. This may organize cell adhesion or microtubule assembly and protrude the raft on the tip of a growing process. b Experimental evidence for ceramide rafts and SLIPS in NPCs. Immunocytochemistry for ceramide and sphingomyelin. Ceramide microdomains at the tip of the cell (arrows) are mostly segregated from SM domains. c Immunocytochemistry for ceramide (Cy5-conjugated) and α-tubulin (Cy3-conjugated, after 2nd fixation and permeabilization). Cy3 (α-tubulin)-to-Cy5 (ceramide) FRET was recorded indicating that ceramide and nascent microtubules form a complex (arrows). The FRET signal was confirmed by acceptor bleaching as described in Wang et al. [2] (not shown).
Ceramide and S1P: Key Regulators of Stem Cell Polarity and Apoptosis

In the previous section, we have discussed a potential non-apoptotic function of ceramide. We will now discuss the mechanism underlying this function and how it is regulated. Our studies have shown that the non-apoptotic function(s) of ceramide depend on a low expression level of PAR-4, a protein that inhibits ceramide-associated aPKC. We have found that there are three stages during ES cell differentiation at which expression of PAR-4 is absent or low: undifferentiated ES cells, suspension EBs, and NPCs [2–5, 113]. Recently, we have reported that in suspension EBs, ceramide is essential for the polarity of primitive ectoderm cells [3]. Ceramide depletes membrane association of aPKC, disrupts the interaction between aPKC and Cdc42, and results in decreased phosphorylation of GSK-3β. The novel ceramide analog S18 restores primitive ectoderm formation, indicating that it is ceramide and not one of its derivatives that regulates cell polarity. Although this suggests a regulatory effect of ceramide on the noncanonical Wnt or cell polarity pathway, further studies are needed to clarify the significance of ceramide for cell polarity in a wider spectrum of cells.

We propose the working model shown in figure 3a to explain the function of ceramide for cell polarity in NPCs and other cell types. Based on our observation that ceramide microdomains co-distribute or even associate with microtubules (fig. 2a, c) [1, 95], we focus on the effect of ceramide-associated aPKC on GSK-3β. GSK-3β phosphorylates many proteins that regulate cell adhesion or formation of microtubules. Key factors are β-catenin, adenomatous polyposis coli (APC), and τ-protein [114–122]. Phosphorylation of β-catenin by GSK-3β renders it susceptible to proteolytic degradation [116], while hyperphosphorylation of τ causes its aggregation in tauopathy, a neurodegenerative disorder that is also involved in the etiology of Alzheimer’s disease [114, 119, 120]. Phosphorylation of APC by GSK-3β disrupts its function in stabilizing the plus end of microtubules [116]. According to our model, ceramide-induced activation of aPKC will result in aPKC-dependent phosphorylation of or inactivation of GSK-3β. Hence, ceramide and S18 should stabilize microtubules while ceramide depletion will destabilize them (fig. 3a).

Figure 3c shows that among the factors that regulate adherens junctions and microtubules, ceramide-activated aPKC and PP2a may complement each other. It is known that PP2a dephosphorylates β-catenin, APC, and τ [115, 120]. Hence, loss of phosphorylation by ceramide-mediated inactivation of GSK-3β (via ceramide-activated aPKC) and enhanced dephosphorylation by ceramide-activated PP2a should act synergistically on promoting the stability of microtubules. Interestingly, GSK-3β can also phosphorylate and inactivate PP2a [123]. Therefore, ceramide can activate PP2a in two ways: by direct binding to PP2a and by inactivating GSK-3β. In contrast to this, ceramide-activated PP2a may also dephosphorylate GSK-3β, thereby antagonizing inactivation of GSK-3β by ceramide-activated aPKC [124]. Clearly, more studies on the ceramide-dependent interplay of aPKC, GSK-3β, and PP2a are needed to unravel these intricate regulatory mechanisms.

PAR-4 is a leucine zipper protein with several functions. It was discovered by differential hybridization to identify pro-apoptotic genes expressed in androgen-dependent prostate cells [125]. Using two hybrid assays it was soon found to be an inhibitor of aPKC and transcriptional co-repressor of Wilms’ tumor suppressor 1 (WT1) [126, 127]. Recently, PAR-4 has gained attention due to its multifaceted function in neural cells. It has been suggested to contribute to neurodegeneration in Alzheimer’s and Parkinson’s disease, and to the etiology of amyotrophic lateral sclerosis and stroke [86, 128–132]. In addition to its pro-apoptotic functions, PAR-4 has been shown to regulate the activity of choline acetyl transferase, to inhibit choline uptake, and to regulate synaptic plasticity [133–135]. In this regard, it may be of interest that PAR-4 has been found to be temporarily associated with the actin cytoskeleton [136]. Our group has described a short form of PAR-4 that acts as dominant negative regulator of apoptosis by forming actin-associated heterodimers with the pro-apoptotic long form of PAR-4 [6].

When the pro-apoptotic form of PAR-4 is expressed, the non-apoptotic effect of ceramide changes fundamentally. Using lipid vesicles made of ceramide and phospholipids (termed Lipid vesicle-Mediated Affinity Chromatography or LIMAC) we have found that association of aPKC with ceramide will enhance the affinity of aPKC to its inhibitor PAR-4 [2]. In the presence of PAR-4, ceramide will not activate aPKC, but on the contrary, enhance its inhibition by PAR-4 (fig. 3b). Because of this, an initial non-apoptotic or even pro-survival function of ceramide can rapidly turn into the induction of apoptosis.

In addition to its immediate cell signaling function, ceramide serves as metabolic precursor for another important cell signaling lipid, sphingosine-1-phosphate (S1P). Ceramide is hydrolyzed by ceramidase to sphingo-
sine, which is then phosphorylated by sphingosine kinase 1 or 2 (SK1 or 2) to S1P (fig. 1a) [137–144]. S1P is a soluble ligand that can bind and activate five isoforms of the S1P receptor [21, 34–36, 39, 145–147]. Knockout mice for SK1 and 2 or S1P receptors have clearly demonstrated the essential function of S1P for vascular and neural development [138]. Recent studies indicate that one of the functions of S1P is to counterbalance ceramide-induced apoptosis [88, 141, 148]. S1P is known to increase phosphorylation of p42/44-MAPK and Akt (protein kinase B), two important protein kinases that inactivate the pro-apoptotic proteins Bad and Bax (fig. 3c) [1, 113, 145, 149–155]. Unlike S1P, ceramide has been shown to reduce the activity of p42/44-MAPK and Akt [26, 113, 154, 156]. Hence, it is tempting to speculate that ceramide and S1P counterregulate the phosphorylation of Bax and Bad, thereby controlling apoptosis and cell survival (fig. 3d).

At this point, it is useful to summarize sphingolipid-regulated cell signaling pathways that allow for a predictive outcome of ceramide and S1P elevation on cell polarity and apoptosis based on the expression profile of receptor and modulator proteins:

Fig. 3. Molecular interactions of ceramide-associated aPKC (working models). a In the absence of PAR-4, ceramide-associated aPKC forms a polarity complex with Par3, Par6, and Cdc42. This may control microtubule assembly and protrude the cell membrane. b In the presence of PAR-4, ceramide-associated aPKC binds to PAR-4, which inhibits its activity and induces apoptosis. c Ceramide activates distinct cell signaling pathways depending on the expression level of PAR-4. In PAR-4(-) cells (left panel), ceramide activates aPKC, which inactivates GSK-3β and stabilizes β-catenin, increases binding of APC to the plus ends of microtubules, and prevents aggregation of τ. Ceramide-activated PP2a may complement this effect on aPKC. In PAR-4(+) cells, ceramide induces inhibition of aPKC by PAR-4, which inactivates NF-κB and PI3K/Akt, two key cell signaling pathways for cell survival. Inhibition of Akt prevents inactivation of Bad/Bax and induces apoptosis. This is antagonized by S1P-mediated activation of Akt.
Pluripotency Factors and Stem Cell Derived-Tumors: Active Elimination of Risky Stem Cells with Novel Ceramide Analogs

One of the major perils using stem cells for therapy is their ability to maintain or (re-)adopt a pluripotent state that endows them with the capacity of forming teratomas (stem cell-derived tumors). Teratoma formation has been reported in roughly half of the studies using embryonic stem (ES) cell-derived stem cell grafts [5, 9, 157–167]. The risk is inversely proportional to the differentiation stage. The more differentiated the stem cells, the lower the probability of teratoma formation. However, even genetically re-programmed adult cells, regardless of initially being stem cells or differentiated cells, form teratomas if endowed with pluripotency factors [168]. Therefore, techniques are needed to prevent teratoma formation from stem cell transplants.

Teratoma formation from ES cells can be avoided by differentiating these cells to a particular progenitor stage that allows for repeated self-renewing of the progenitor cells. Continuous passaging of neural progenitors will eventually ‘dilute out’ pluripotent cells and minimize the risk of teratomas. However, in stem cell therapy, size matters. In experiments with mice, the number of transplanted cells is usually in the range of $10^5$–$10^6$ cells/injection. This number is pre-determined by the injection technique: the small volume of the cell suspension does simply not accommodate a larger number of cells if a single dose is injected. A human brain, however, is 1,000-times larger than a mouse brain. It is questionable that this low number of cells will be able to repair tissue, in particular, if it is not desired that the cells retain the capacity of repeated cell division after transplantation. Our studies have shown that within a population of embryoid body-derived cells at the stage of generating NPCs, up to 30% of the cells may retain pluripotency and therefore pose a serious risk of teratoma formation [5]. In terms of risk/benefit assessment of stem cell therapy, a simple rule may work against us: the number of injected cells will need to be proportional to the size of damage, while it takes just one cell to form a tumor.

Stem cell therapy without techniques actively eliminating teratoma-forming stem cells may only be successful if combined with genetic engineering of the transplanted cells. Fluorescent or surface proteins expressed under the control of a progenitor-specific promoter (e.g. nestin, Sox-1, Olig-2) have been used to ‘purify’ NPCs or oligodendrocyte precursors by fluorescence- or magnetic-activated cell sorting (FACS or MACS) and to rid them of residual pluripotent cells [169–172]. Conversely, fluorescent protein expression under the control of the Oct-4 promoter can be used to remove pluripotent stem cells or to confirm loss of pluripotency in the graft. However, these methods will need stable transfection with a transgene that will be present in the graft, regardless of the gene product being expressed or not. While certainly feasible for animal studies, it will add another layer of intricacy for approval in human stem cell therapy.

Alternatively, residual pluripotent stem cells can be eliminated by harnessing an intrinsic sensitivity toward apoptosis inducers. We have shown for the first time that these cells co-express the pluripotency marker Oct-4 and the apoptosis sensitizer PAR-4 [5]. As discussed in the previous sections, PAR-4 is an inhibitor protein that binds to aPKC when associated with ceramide. Inhibition of aPKC induces apoptosis. Hence, simply incubating differentiating ES cells at the stage of forming NPCs with the novel ceramide analog S18 eliminates Oct-4(+) cells because they are sensitized to ceramide due to the co-expression of PAR-4. Our studies have shown that this technique can be used to prevent teratoma formation when transplanting neural stem cells derived from ES cells [5].

Active elimination of teratoma-forming stem cells from a graft using novel ceramide analogs was possible because we determined the protein expression profile, in particular pluripotency and sensitivity to apoptosis inducers, in these cells. However, in ongoing studies, we discovered that a small portion of useful NPCs may also be sensitive toward ceramide because they express PAR-4. Profiling for factors that allow for protection against ceramide will form a rationale to use additional drugs to protect these ceramide-sensitive cells.
Making SENSE of Sphingolipids: Design of Sphingolipid-Enhanced Neural Stem Cells

The in vitro differentiation protocol used in our group follows McKay’s original procedure of inducing neural differentiation by serum deprivation of ES cells [4, 5, 173, 174]. Fibroblast-free ES cells are first cultivated as suspension embryoid bodies (EBs) and then as attached EBs. Attached EBs are dissociated and re-plated in serum-free medium in the presence of basic fibroblast growth factor. This protocol consistently yields a homogenous population of NPCs that are self-renewing and express well-characterized markers such as Sox1 and nestin. ES cell-derived NPCs can be further differentiated to neurons and glial cells in vitro and in vivo after transplantation into mouse brain.

We have shown that ceramide is elevated in in vitro differentiating ES cells and that it is essential for the morphogenesis of the primitive ectoderm layer at the stage of suspension EBs [2–4, 113]. However, the role of ceramide changes dramatically as soon as suspension EBs have attached. The expression of PAR-4 is up-regulated and renders the differentiating ES cells susceptible to ceramide-inducible apoptosis. Depending on the expression level of ceramide and PAR-4, cells will differentiate to NPCs concurrent with up-regulation of nestin (PAR-4(−) cells), or they will undergo apoptosis (PAR-4(+) cells). We have shown that asymmetric cell division will result in the distribution of PAR-4 to one and nestin to the other daughter cell [4]. The daughter cell that inherits PAR-4 can be eliminated by supplementing the medium with ceramide or novel ceramide analogs, while the nestin expressing daughter cell can be used for stem cell transplantation. As discussed in the previous section, we have used this technique to rid a neural progenitor graft of residual pluripotent, teratoma-forming stem cells.

In further studies, however, we have found that a small subpopulation (<5%) of NPCs express low levels of nestin and high levels of PAR-4. Because the characterization of these cells is still a matter of ongoing research in our laboratory, we have termed the nestin(low)/PAR-4(+) cells neural precursor cells 2 (NPC2) as opposed to NPC1, the ‘classical’ nestin (high)/PAR-4(−) neural progenitors. Unfortunately, NPC2 cells are eliminated by incubation with S18 due to the expression of PAR-4. In an attempt to protect these cells from ceramide- or ceramide analog-induced apoptosis, we determined the expression profile of cell signaling pathways that counteract ceramide by promoting cell survival.

In a preceding section, we have discussed that S1P is a natural antagonist of ceramide-inducible apoptosis (fig. 3c). We determined the expression profile for S1P receptors to test whether S1P can rescue NPC2 cells from S18-induced apoptosis. NPC2 cells, but not residual pluripotent (Oct-4(+) cells) express the S1P receptor S1P1 (fig. 4a) [unpubl. results]. Consistent with this expression, S1P or its analog FTY720 protects NPC2 cells from S18-inducible apoptosis, which increases their number by fourfold. Accordingly, the combined administration of S18 and FTY720 eliminates teratoma-forming cells (Oct-4(+)/PAR-4(+)/S1P1(−)) as well as it promotes survival of NPC2 cells (Oct-4(−)/PAR-4(+)S1P1(+) (fig. 4b). In addition to S1P1, NPC2 cells express the oligodendrocyte precursor markers A2B5 epitope (fig. 4c) and NG2 proteoglycan. Thus, they may be similar (or even identical) to ES cell-derived oligodendrocyte precursor cells described in other studies [172, 175–182]. We are currently investigating the differentiation potential and use of NPC2 cells for stem cell therapy.

Concluding Remarks

Studies in our laboratory have shown that profiling of pro-apoptotic or pro-survival factors can guide the design of novel protocols for stem cell differentiation. To our knowledge, this is the first time that profiling of cell-signaling factors responding to sphingolipids has been used to design stem cell differentiation protocols. Figure 4B summarizes our results and their significance for stem cell therapy. The first profile to be determined is that of pluripotency factors such as Oct-4. If Oct-4 is expressed cells are at risk to form teratomas. We have found that Oct-4 is co-expressed with the apoptosis sensitizer PAR-4 [4, 5]. Hence, ceramide analogs such as S18 can be used to eliminate teratoma-forming cells. However, characterizing a profile of pro-apoptotic proteins such as PAR-4 may show that other, Oct-4(−) cells are also sensitive toward apoptosis. Hence, it will be necessary to determine a profile of anti-apoptotic, pro-survival factors that can be used to rescue Oct-4(−)/PAR-4(+) cells. We found that expression of S1P1 on NPC2 cells is such a factor. Accordingly, we use S1P or FTY720 to rescue these cells from ceramide or S18-induced apoptosis. Of course, this protocol only works if risk factor-expressing cells (e.g. teratoma-forming stem cells) do not express S1P receptors, the activation of which would antagonize S18-induced apoptosis.
Our results suggest that incubation of stem cells with the right choice of sphingolipids does not only eliminate teratoma-forming cells but may also sustain cell polarity and promote differentiation. The strategy of making SENSe may thus have broader implications for designing protocols that increase the performance of stem cells. This may include enhancement of adult stem cells used for transplantation, e.g. bone marrow stem cells, but also endogenous progenitor cells. Most recently, it has been shown that S1P and FTY720 promote survival and differentiation of primary cultured oligodendrocyte precursors [183, 184]. FTY720 is already used for clinical trials to treat multiple sclerosis, mainly because of its immuno-suppressing activity [185–189]. Based on these studies, it is reasonable to speculate that FTY720 may also spur remyelination because it promotes survival and differentiation of endogenous oligodendrocyte precursors [183]. This example shows that sphingolipids will have a promising future as important components for the design of novel stem cell therapies and treatment of neurodegenerative disorders.

**Acknowledgement**

This work was supported by NIH grant R01NS046835.
References


Sphingolipid-Enhanced Neural Stem Cells


